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Abstract ATRIPLA is licensed for use only in HIV-
positive persons whose viral loads\50 for C3 months. We
investigated the use of ATRIPLA as first-line antiretroviral
therapy (ART) in EuroSIDA using a web-based survey
performed in Autumn 2012. 96/112 clinics (85.7 %)
completed the survey. Recommendations when initiating
first-line ART was TRUVADA plus efavirenz in 36
(37.5 %), ATRIPLA in 35 (36.5 %), a different first-line
regimen in 12 clinics (12.5 %), and no recommendation in
7 clinics (7.3 %). ATRIPLA was commonest in Northern
(15/21 clinics; 71.4 %), and least common in Eastern
Europe (2/31 clinics; 6.5 %; p \ 0.0001). Over one-third
of the participating clinics in this survey were using
ATRIPLA as first-line antiretroviral therapy, despite EMA
recommendations.
Background
ATRIPLA is a once-daily fixed-dose combination of a non-
nucleoside reverse transcriptase inhibitor (NNRTI) efavi-
renz (EFV; 600 mg), and the nucleoside reverse trans-
criptase inhibitors (NRTI) tenofovir disoproxil fumarate
(TDF; 300 mg) and emtricitabine (FTC; 200 mg), which
have potent activity against HIV-1 infection [1, 2]. The
European Medicines Agency (EMA) has licensed ATRI-
PLA for use only in HIV-positive persons whose levels of
HIV in the blood (viral loads) have been below 50 copies/
ml for more than 3 months on their current HIV treatment
combination [3]. The reasons for the current EMA labelling
is that intake of tenofovir is normally with food, while
ATRIPLA is usually taken at night prior to bed and
therefore in a semi-fasting state [3, 4]. Demonstration of
non-inferior viral outcome from use of ATRIPLA versus
TRUVADA ? efavirenz would require a sizable phase IV
trial, which has not yet been performed. Despite this, a
sizeable proportion of persons initiating antiretroviral
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therapy are believed to start ATRIPLA and not on the
individual components as recommended by the label. It is
important to understand the extent to which centres treating
HIV-positive individuals adhere to EMA recommendations
in general. The aim of this survey was to assess ATRIPLA
use as first-line antiretroviral therapy in daily clinical
management of HIV-infected persons from across Europe.
Methods
The EuroSIDA study was initiated in 1994, and is a pro-
spective observational cohort study of more than 18,000
HIV-positive persons followed in 112 hospitals in 33
European countries, plus Israel and Argentina (details at
http://www.chip.dk). A cross-sectional web-based survey
of HIV clinics participating in EuroSIDA was used to
investigate the use of ATRIPLA, or its components, as
first-line antiretroviral therapy in HIV-infected persons in
diverse clinical settings in Europe. The survey was com-
pleted as an electronic survey using REDCapTM, in
agreement with the REDCap Consortium, Vanderbilt
University included information collected from treating
physicians about their normal department policy for treat-
ment of HIV-infected persons initiating a first-line anti-
retroviral therapy regimen containing ATRIPLA as a fixed-
dose once-daily combination tablet, or its individual com-
ponents in Europe. For the purposes of descriptive analysis,
EuroSIDA has been divided into four geographical regions,
as previously described—South, Central West, North, East
and Argentina [5]. For the present analysis, Argentina (only
one clinic participating in EuroSIDA) has been merged
with data from Southern Europe.
Results
A total of 96/112 clinics (85.7 %) completed the survey.
Summary characteristics of those who completed or did not
complete the survey are shown in Table 1, with few dif-
ferences between participating and non-participating sites.
Clinics with persons with a higher median CD4 count at
recruitment were less likely to participate [adjusted odds
ratio (aOR) 0.51 per 50/mm3 higher median CD4; 95 %
Table 1 Comparison of summary statistics between participating and non-participating centres
Excluded Included p
N % N %
N 16 14.3 96 85.7
Region
South 7 24.1 22 75.9 0.35
Central West 3 12.0 22 88.0
North 3 12.5 21 87.5
East 3 8.8 31 91.2
Median IQR Median IQR
Male gender 74.9 65.1–85.5 75.0 67.2–81.0 0.61
Age (years) 35.6 33.8–38.1 36.6 33.9–39.3 0.40
White race 94.0 88.7–98.2 94.6 83.7–99.0 0.91
Homosexual 34.4 16.9–63.8 36.2 19.4–54.7 0.65
IDU 11.8 4.2–38.0 20.0 6.6–38.5 0.41
Heterosexual 26.3 17.3–42.0 27.5 20.0–36.3 0.76
Prior AIDS 23.4 14.8–28.1 27.5 19.2–33.5 0.31
Started cART 32.3 10.5–63.7 50.4 32.2–72.1 0.078
ARV naı¨ve 31.0 20.9–49.9 25.3 17.1–35.3 0.17
VL \400 57.0 44.0–67.1 59.6 46.0–70.8 0.44
CD4 (/mm3) 372 224–465 339 257–400 0.55
VL (log10cp/ml) 2.4 1.7–2.9 2.6 1.7–3.0 0.57
Enrollment (month/year) 3/99 7/94–3/04 1/02 2/97–5/06 0.16
Figures in tables are based on summary statistics from the main EuroSIDA clinical database, and are not part of the data collected in the survey.
The proportion of, for example, males, within each centre has been extracted from the main database, and the figure in the table is the median of
these proportions. Similarly, the median CD4 at enrolment within each centre has been extracted, and the figure in the table represents the median
of these medians
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confidence interval (CI) 0.32–0.81, p = 0.0043)], while
clinics with a higher median proportion on cART were
more likely to participate (aOR 1.34 per 10 % higher; 95 %
CI 0.99–1.80, p = 0.057), as were clinics with a later
median date of enrolment in EuroSIDA (aOR 1.28 per year
later; 95 % CI 1.02–1.60, p = 0.030). Of note, there were
no differences between regions in terms of participation in
the survey.
The median number of persons cared for in the clinics
surveyed was 1,200 [interquartile range (IQR 665–2,150)],
with no significant variation across the regions surveyed.
The median proportion on cART was 80 % (IQR
70–90 %), with the highest proportion in Central West and
Northern Europe (both median 85 %, IQR 80–90 %), fol-
lowed by Southern Europe (median 80 %, IQR 70–90 %)
and the lowest proportion in Eastern Europe (median 60 %,
IQR 35–75 %, p \ 0.0001).
36 clinics (37.5 %) indicated that the current recommen-
dation when initiating first-line antiretroviral therapy was
that tenofovir and emtricitabine are administered as one
tablet, with efavirenz administered separately; 35 clinics
(36.5 %) indicated that ATRIPLA was the current recom-
mendation; 12 clinics (12.5 %) indicated that they usually
use a different first-line regimen and 7 clinics (7.3 %) indi-
cated that the decision was up to the treating physician with
no general recommendation. Six clinics (6.3 %), all from
Eastern Europe, said the three components were adminis-
tered separately. There were significant differences between
regions (Fig. 1) (p \ 0.0001). Among the six clinics
responding that the three components were administered
separately, one was due to a local decision and financial
considerations, one was due to national guidelines, one due to
a clinical decision, and one for purely financial reasons. Two
clinics stated it was because ATRIPLA was not routinely
available in their country (Hungary and Romania).
Of the 35 clinics which used ATRIPLA as the first-line
regimen, 18 (51.4 %) stated it was a local decision, 15
(42.9 %) due to national guidelines, 8 (22.9 %) due to
European guidelines and 4 (11.4 %) for other reasons.
There was some overlap between reasons, as clinics were
allowed to indicate more than one choice; two clinics
indicated it was due to both national guidelines and a local
decision, six clinics stated it was due to national and
European guidelines and two due to local decisions and
European guidelines. There were no significant regional
differences in the proportion of clinics indicating ‘local
decision’ as reason for choosing ATRIPLA as initial
therapy. Of the 18 clinics where it was based on local
decision, 18 stated feasibility as the reason for use (100 %),
1 (5.6 %) also stated it was a financial decision. Among the
15 clinics which stated they used ATRIPLA due to national
guidelines, 14 clinics (93.3 %) indicated that this was due
to feasibility, 4 clinics (26.7 %) also stated it was due to
financial considerations (including 3 clinics who stated
feasibility), and 1 clinic (6.7 %) stated it was due to effi-
cacy. Of the 4 clinics which stated that ARTPLA was used
as initial therapy for other reasons, these included that it
was considered to be state-of-the-art therapy, financial
reasons and in 2 clinics at the individuals request. A total of
30 clinics (85.7 %) stated ATRIPLA was used as a first-
line regimen for feasibility either as part of local or
national decision-making.
Conclusion
Based on this survey of 96 clinics participating in EuroS-
IDA, it was apparent that a substantial proportion of clinics
do not follow the recommended labelling for ATRIPLA,
since 36.5 % of responding clinics use ATRIPLA as first-
Fig. 1 Current
recommendations for first-line
cART
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line therapy, primarily due to feasibility reasons. Six clin-
ics, all in Eastern Europe, started the three components of
ATRIPLA separately, and the observed regional differ-
ences are likely to some extent based on ATRIPLA
availability and cost of the combination tablet in the
Eastern European region.
One-third of participating clinics chose ATRIPLA as
first-line antiretroviral therapy, despite the EMA licensing
the regimen to HIV-positive persons with viral suppression
for at least 3 months [3]. Of note, major international
guidelines do not include a specific recommendation
regarding this product information, but highlight the co-
formulation of the agents and the availability of a single
tablet regimen as an important advantage of this regimen
[6–8]. In addition, results from 2012 to 2013 suggest that
virologic response to ATRIPLA as first-line antiretroviral
therapy, administered on an empty stomach, was similar to
that of a first-line regimen of once-daily elvitegravir,
cobicistat, emtricitabine and tenofovir, and was equally
high in persons with baseline viral loads above
100,000 copies/ml [9, 10]. The difference between the cost
of ATRIPLA and individual components also likely plays
an important role in prescribing, but varies from country to
country and even from clinic to clinic, likely depending on
a number of factors including local contract negotiation
between hospitals and pharmaceutical companies.
Limitations of this study include that not all clinics
participated in the survey, although our response rate was
[85 %. Centres participating in EuroSIDA tend to be
centres of excellence and therefore may not be represen-
tative of all clinics in the European region. In addition, this
survey was performed in 2012, and represents a cross-
sectional survey of clinical practice at that time, which may
since have changed. The major strength of this survey is
the regional representation across Europe. We did not
collect information on recommendations of the clinics as to
when to take efavirenz and truvada when administered
separately. Clinics may have advised persons to take ef-
avirenz and truvada at night before bed to avoid twice-daily
medication. Non-adherence to EMA guidelines may
therefore be higher than shown in this report. Unfortu-
nately, due to limited power, we were not able to compare
the virological response following initiation of ATRIPLA
as first-line antiretroviral therapy according to how it was
initiated within the EuroSIDA study.
To conclude, over one-third of the participating clinics
were using ATRIPLA as first-line antiretroviral therapy,
despite recommendations that this regimen only be used in
HIV-positive persons with [3 months virological sup-
pression (\50 copies/ml) on their current regimen. Sites in
many European countries report not adhering to the
ATRIPLA summary of product characteristics in 2012, and
the regulatory and legal implications to the individual sites
or for individuals are unclear. Use of ATRIPLA was
highest in Northern Europe, while Eastern and Southern
Europe more commonly used truvada plus efavirenz. Main
reasons cited include cost and availability.
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Appendix: The EuroSIDA Study Group
The multi-centre study group on EuroSIDA (national
coordinators in parenthesis).
Argentina: (M. Losso), M. Kundro, Hospital JM Ramos
Mejia, Buenos Aires.
Austria: (N. Vetter), Pulmologisches Zentrum der Stadt
Wien, Vienna; R. Zangerle, Medical University Innsbruck,
Innsbruck.
Belarus: (I. Karpov), A. Vassilenko, Belarus State
Medical University, Minsk, V.M. Mitsura, Gomel State
Medical University, Gomel; O. Suetnov, Regional AIDS
Centre, Svetlogorsk.
Belgium: (N. Clumeck), S. De Wit, M. Delforge, Saint-
Pierre Hospital, Brussels; R. Colebunders, Institute of
Tropical Medicine, Antwerp; L Vandekerckhove, Univer-
sity Ziekenhuis Gent, Gent.
Bosnia-Herzegovina: (V Hadziosmanovic), Klinicki
Centar Univerziteta Sarajevo, Sarajevo.
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Bulgaria: (K Kostov), Infectious Diseases Hospital,
Sofia.
Croatia: (J Begovac), University Hospital of Infectious
Diseases, Zagreb.
Czech Republic: (L Machala), D Jilich, Faculty Hospital
Bulovka, Prague; D Sedlacek, Charles University Hospital,
Plzen.
Denmark: (J Nielsen), G Kronborg,T Benfield, M Lar-
sen, Hvidovre Hospital, Copenhagen; J Gerstoft, T Kat-
zenstein, A-B E Hansen, P Skinhøj, Rigshospitalet,
Copenhagen; C Pedersen, Odense University Hospital,
Odense; L Ostergaard, Skejby Hospital, Aarhus.
Estonia: (K Zilmer), West-Tallinn Central Hospital,
Tallinn; Jelena Smidt, Nakkusosakond Siseklinik, Kohtla-
Ja¨rve.
Finland: (M Ristola), Helsinki University Central Hos-
pital, Helsinki.
France: (C Katlama), Hoˆpital de la Pitie´-Salpe´tie`re,
Paris; J-P Viard, Hoˆpital Necker-Enfants Malades, Paris;
P-M Girard, Hospital Saint-Antoine, Paris; JM Livrozet,
Hoˆpital Edouard Herriot, Lyon; P Vanhems, University
Claude Bernard, Lyon; C Pradier, Hoˆpital de l’Archet,
Nice; F Dabis, D Neau, Unite´ INSERM, Bordeaux.
Germany: (J Rockstroh), Universita¨ts Klinik Bonn; R
Schmidt, Medizinische Hochschule Hannover; J van Lun-
zen, O Degen, University Medical Center Hamburg-Ep-
pendorf, Infectious Diseases Unit, Hamburg; HJ Stellbrink,
IPM Study Center, Hamburg; mM Bickel, JW Goethe
University Hospital, Frankfurt; J Bogner, Medizinische
Poliklinik, Munich; G. Fa¨tkenheuer, Universita¨t Ko¨ln,
Cologne.
Greece: (J Kosmidis), P Gargalianos, G Xylomenos, J
Perdios, Athens General Hospital; G Panos, A Filandras, E
Karabatsaki, 1st IKA Hospital; H Sambatakou, Ippokration
Genereal Hospital, Athens.
Hungary: (D Banhegyi), Szent La´slo´ Hospital,
Budapest.
Ireland: (F Mulcahy), St. James’s Hospital, Dublin.
Israel: (I Yust), D Turner, M Burke, Ichilov Hospital, Tel
Aviv; S Pollack, G Hassoun, Rambam Medical Center,
Haifa; S Maayan, Hadassah University Hospital, Jerusalem.
Italy: (S Vella), Istituto Superiore di Sanita`, Rome; R
Esposito, I Mazeu, C Mussini, Universita` Modena, Mode-
na; C Arici, Ospedale Riuniti, Bergamo; R Pristera,
Ospedale Generale Regionale, Bolzano; F Mazzotta, A
Gabbuti, Ospedale S Maria Annunziata, Firenze; V Vullo,
M Lichtner, University di Roma la Sapienza, Rome; A
Chirianni, E Montesarchio, M Gargiulo, Presidio Ospe-
daliero AD Cotugno, Monaldi Hospital, Napoli; G An-
tonucci, A Testa, G D‘Offizi, C Vlassi, M Zaccarelli, A
Antorini, Istituto Nazionale Malattie Infettive Lazzaro
Spallanzani, Rome; A Lazzarin, A Castagna, N Gianotti,
Ospedale San Raffaele, Milan; M Galli, A Ridolfo, Osp.
L. Sacco, Milan; A d’Arminio Monforte, Istituto Di Clinica
Malattie Infettive e Tropicale, Milan.
Latvia: (B Rozentale), I Zeltina, Infectology Centre of
Latvia, Riga.
Lithuania: (S Chaplinskas), Lithuanian AIDS Centre,
Vilnius.
Luxembourg: (T Staub), R Hemmer, Centre Hospitalier,
Luxembourg.
Netherlands: (P Reiss), Academisch Medisch Centrum
bij de Universiteit van Amsterdam, Amsterdam.
Norway: (V Ormaasen), A Maeland, J Bruun, Ulleva˚l
Hospital, Oslo.
Poland: (B Knysz) J Gasiorowski, Medical University,
Wroclaw; A Horban, E Bakowska, Centrum Diagnostyki i
Terapii AIDS, Warsaw; A Grzeszczuk, R Flisiak, Medical
University, Bialystok; A Boron-Kaczmarska, M Pynka, M
Parczewski, Medical Univesity, Szczecin; M Beniowski, E
Mularska, Osrodek Diagnostyki i Terapii AIDS, Chorzow;
H Trocha, Medical University, Gdansk; E Jablonowska, E
Malolepsza, K Wojcik, Wojewodzki Szpital Spec-
jalistyczny, Lodz.
Portugal: (F Antunes), M Doroana, L Caldeira, Hospital
Santa Maria, Lisbon; K Mansinho, Hospital de Egas
Moniz, Lisbon; F Maltez, Hospital Curry Cabral, Lisbon.
Romania: (D Duiculescu), Spitalul de Boli Infectioase si
Tropicale: Dr. Victor Babes, Bucharest.
Russia: (A Rakhmanova), Medical Academy Botkin
Hospital, St Petersburg; N Zakharova, St Petersburg AIDS
Centre, St Peterburg; S Buzunova, Novgorod Centre for
AIDS, Novgorod.
Serbia: (D Jevtovic), The Institute for Infectious and
Tropical Diseases, Belgrade.
Slovakia: (M Mokra´sˇ), D Stanekova´, De´rer Hospital,
Bratislava. Slovenia: (J Tomazic), University Clinical
Centre Ljubljana, Ljubljana.
Spain: (J Gonza´lez-Lahoz), V Soriano, P Labarga, J
Medrano, Hospital Carlos III, Madrid; S Moreno, J.
M. Rodriguez, Hospital Ramon y Cajal, Madrid; B Clotet,
A Jou, R Paredes, C Tural, J Puig, I Bravo, Hospital
Germans Trias i Pujol, Badalona; JM Gatell, JM Miro´,
Hospital Clinic i Provincial, Barcelona; P Domingo, M
Gutierrez, G Mateo, MA Sambeat, Hospital Sant Pau,
Barcelona.
Sweden: (A Blaxhult), Venhaelsan-Sodersjukhuset,
Stockholm; L Flamholc, Malmo¨ University Hospital,
Malmo¨; A Thalme, A Sonnerborg, Karolinska University
Hospital, Stockholm.
Switzerland: (B Ledergerber), R Weber, University
Hospital, Zu¨rich; P Francioli, M Cavassini, Centre Hos-
pitalier Universitaire Vaudois, Lausanne; B Hirschel, E
Boffi, Hospital Cantonal Universitaire de Geneve, Geneve;
H Furrer, Inselspital Bern, Bern; M Battegay, L Elzi,
University Hospital Basel.
A survey of ATRIPLA use in clinical practice 761
123
Ukraine: (E Kravchenko), N Chentsova, Kiev Centre for
AIDS, Kiev; V Frolov, G Kutsyna, Luhansk State Medical
University; Luhansk; S Servitskiy, Odessa Region AIDS
Center, Odessa; M Krasnov, Kharkov State Medical Uni-
versity, Kharkov.
United Kingdom: (S Barton), St. Stephen’s Clinic,
Chelsea and Westminster Hospital, London; AM Johnson,
D Mercey, Royal Free and University College London
Medical School, London (University College Campus); A
Phillips, MA Johnson, A Mocroft, Royal Free and Uni-
versity College Medical School, London (Royal Free
Campus); M Murphy, Medical College of Saint Bartholo-
mew’s Hospital, London; J Weber, G Scullard, Imperial
College School of Medicine at St. Mary’s, London; M
Fisher, Royal Sussex County Hospital, Brighton; C Leen,
Western General Hospital, Edinburgh.
Steering Committee: J Gatell, B Gazzard, A Horban, I
Karpov, B Ledergerber, M Losso, A D’Arminio Monforte,
C Pedersen, A Rakhmanova, M Ristola, J Rockstroh
(Chair), S De Wit (Vice-Chair).
Additional voting members: J Lundgren, A Phillips, P
Reiss.
Coordinating Centre Staff: O Kirk, A Mocroft, A Cozzi-
Lepri, D Grint, A Schultze, L Shepherd, M Sabin, D Po-
dlekareva, J Kjær, L Peters, J Nielsen, J Tverland, A H
Fischer.
EuroSIDA representatives to EuroCoord: O Kirk, A
Mocroft, J Grarup, P Reiss, A Cozzi-Lepri, R Thiebaut, J
Rockstroh, D Burger, R Paredes, J Kjær. L Peters.
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